The historical rank and industry rank for AstraZeneca Pharma India's Days Payable or its related term are showing as below:
NSE:ASTRAZEN'
s Days Payable Range Over the Past 10 Years
Min: 115.04 Med: 183.91 Max: 214.27
Current: 157.74
During the past 13 years, AstraZeneca Pharma India's highest Days Payable was 214.27. The lowest was 115.04. And the median was 183.91.
NSE:ASTRAZEN's Days Payable is ranked better than 76.74% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:ASTRAZEN: 157.74
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTRAZEN vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Days Payable distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AstraZeneca Pharma India's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Days Payable of 181.16 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AstraZeneca Pharma India and its competitors. This is near median its historical median of 183.91. Over the past decade, AstraZeneca Pharma India's Days Payable has ranged from 115.04 to 214.27. According to the industry distribution chart, AstraZeneca Pharma India ranks #214 out of 920 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is AstraZeneca Pharma India's Days Payable too high?
AstraZeneca Pharma India's current Days Payable of 181.16 is near median its 10-year median of 183.91. Over the past 10 years, this metric has ranged from a low of 115.04 to a high of 214.27. The Drug Manufacturers industry median Days Payable is 90.84. AstraZeneca Pharma India's value of 181.16 is 99.4% above this industry median. Based on the distribution chart, AstraZeneca Pharma India ranks #214 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca Pharma India has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #214 out of 920 companies for Days Payable. This places AstraZeneca Pharma India in the top 23% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.84. AstraZeneca Pharma India's value of 181.16 is 99.4% above this benchmark. Historically, AstraZeneca Pharma India's own Days Payable has ranged from 115.04 to 214.27 over the past decade. While the company's 10-year median is 183.91 vs. the industry median of 90.84, AstraZeneca Pharma India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca Pharma India's current Days Payable of 181.16 is 99.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Days Payable is 181.16, which is near median its own 10-year median of 183.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹10,870.93, compared to a current price of ₹8,391.00 — trading 22.8% below its estimated fair value. The current Days Payable is 181.16, which is near median its 10-year median of 183.91 and 99.4% above the Drug Manufacturers industry median of 90.84. AstraZeneca Pharma India's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Days Payable is 181.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹8,391.00 is trading 22.8% below its estimated GF Value™ of ₹10,870.93.
GuruFocus considers AstraZeneca Pharma India to be Modestly Undervalued.
Key valuation signals for NSE:ASTRAZEN:
Days Payable: 181.16 (near median its 10-year median of 183.91)
GF Value™: ₹10,870.93 vs. price of ₹8,391.00 (22.8% below fair value)
Industry Position: 99.4% above the Drug Manufacturers median (#214 of 920)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
92GF Score
Get the complete analysis for NSE:ASTRAZEN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
